A new era of prospective real-world safety evaluation: Primary report of XIENCE v USA (XIENCE v Everolimus Eluting Coronary Stent System Condition-of-Approval Post-Market Study)

JACC: Cardiovascular Interventions

Volumn 4, Issue 12, 2011, Pages 1298-1309

  Krucoff, Mitchell W ^a   Rutledge, David R ^b   Gruberg, Luis ^c   Jonnavithula, Lalitha ^b   Katopodis, John N ^d   Lombardi, William ^e   Mao, Vivian W ^b   Sharma, Samin K ^f   Simonton, Charles A ^b   Tamboli, Hoshedar P ^g   Wang, Jin ^b   Wilburn, Olivia ^b   Zhao, Weiying ^b   Sudhir, Krishnankutty ^b   Hermiller, James B ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ABBOTT VASCULAR   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d Tallahassee Research Institute   (United States)

^e North Cascade Cardiology and St Joseph Hospital   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Bay Area Cardiology Associates   (United States)

^h St Vincent Heart Center of Indiana   (United States)

Author keywords

drug eluting stent(s); dual antiplatelet therapy; everolimus; percutaneous coronary intervention; real world; stent; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE; DEVICE APPROVAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BENCHMARKING; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DEVICE APPROVAL; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84255168681     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2011.08.010     Document Type: Article

References (21)

1. A. Farb, A.B. Boam Stent thrombosis redux: the FDA perspective N Engl J Med 356 2007 984 987 (Pubitemid 46376798)
2. S. Garg, P. Serruys, Y. Onuma 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (clinical Evaluation of the Xience V everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 2 2009 1190 1198
3. P.N. Ruygrok, M. Desaga, F. Van Den Branden One year clinical follow-up or the XIENCE V everolimus-eluting stent system in the treatment of de novo native coronary artery lesions: the SPIRIT II study EuroIntervention 3 2007 315 320
4. P.W. Serruys, P. Ruygrok, J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
5. G.W. Stone, M. Midei, W. Newman Randomised comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation 119 2009 680 686
6. G.W. Stone, M. Midei, W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomised trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
7. G.W. Stone, A. Rizvi, W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
8. D.E. Cutlip, W. Stephan, M. Roxana Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
9. K. Thygesen, J.S. Alpert, H.D. White Universal definition of myocardial infarction Circulation 116 2007 2634 2653 (Pubitemid 350182388)
10. P. Vranckx, D.E. Cutlip, R. Mehran Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
11. C.L. Grines, R.O. Bonow, D.E. Casey Jr. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Coll Cardiol 49 2007 734 739 (Pubitemid 46210116)
12. S.C. Smith Jr., T.E. Feldman, J.W. Hirshfeld Jr. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention) J Am Coll Cardiol 47 2006 216 235 (Pubitemid 43005194)
13. S.B. King, S.C. Smith Jr., A.K. Jacobs 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209
14. A.J. Kirtane, A. Gupta, S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119:3 2009 198 206
15. E. Kedhi, K.S. Joesoef, E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
16. P.W. Serruys, S. Silber, S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
17. P. Urban, A. Abizaid, A. Banning e-SELECT Investigators Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry J Am Coll Cardiol 57 2011 1445 1454 29
18. J.M. Lasala, D.A. Cox, D. Dobies Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the Taxus ARRIVE registries Circ Cardiovasc Interv 2 2009 285 293
19. C. Lotan, I.T. Meredith, L. Mauri, M. Liu, M.T. Rothman Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-five registry J Am Coll Cardiol Intv 2 2009 1227 1235
20. F. Airoldi, A. Colombo, N. Morici Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 2007 745 754 (Pubitemid 47255992)
21. J.M. Lasala, D.A. Cox, D. Dobies Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry Catheter Cardiovasc Interv 72 2008 433 445